Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameVisen Pharma-B
Stock Code02561
Company Full NameVISEN Pharmaceuticals
Industry醫療保健
Principal Activities公司是一家處于研發后期、產品接近商業化的生物制藥公司,專注于在中國(包括香港、澳門及臺灣)提供特定內分泌疾病的治療方案。
Listing Date2025-03-21
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省蘇州市九章路69號恒泰理想創新大廈B座3樓3-108室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.visenpharma.com/cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 68.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 6,880
Par ValueTo be extracted
Offer Period2025-03-13 to 2025-03-18
Global Offering Shares11,385,000 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)Morgan Stanley Asia Limited CE AAD291
Cornerstone Share65.1%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 783,288,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 6,880
2 lots 200 HK$ 13,760
3 lots 300 HK$ 20,640
4 lots 400 HK$ 27,520
5 lots 500 HK$ 34,400
6 lots 600 HK$ 41,280
7 lots 700 HK$ 48,160
8 lots 800 HK$ 55,040
9 lots 900 HK$ 61,920
10 lots 1,000 HK$ 68,800
15 lots 1,500 HK$ 103,200
20 lots 2,000 HK$ 137,600
25 lots 2,500 HK$ 172,000
30 lots 3,000 HK$ 206,400
35 lots 3,500 HK$ 240,800
40 lots 4,000 HK$ 275,200
45 lots 4,500 HK$ 309,600
50 lots 5,000 HK$ 344,000
60 lots 6,000 HK$ 412,800
70 lots 7,000 HK$ 481,600
80 lots 8,000 HK$ 550,400
90 lots 9,000 HK$ 619,200
100 lots 10,000 HK$ 688,000
200 lots 20,000 HK$ 1,376,000
300 lots 30,000 HK$ 2,064,000
400 lots 40,000 HK$ 2,752,000
500 lots 50,000 HK$ 3,440,000
600 lots 60,000 HK$ 4,128,000
700 lots 70,000 HK$ 4,816,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 80,000 HK$ 5,504,000
900 lots 90,000 HK$ 6,192,000
1,000 lots 100,000 HK$ 6,880,000
1,500 lots 150,000 HK$ 10,320,000
2,000 lots 200,000 HK$ 13,760,000
2,500 lots 250,000 HK$ 17,200,000
3,000 lots 300,000 HK$ 20,640,000
3,500 lots 350,000 HK$ 24,080,000
4,000 lots 400,000 HK$ 27,520,000
4,500 lots 450,000 HK$ 30,960,000
4,950 lots 495,000 HK$ 34,056,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 2.51B
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +273%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 347.78 million
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investmentapproximately USD 190 million
First Day CloseHK$ 68.8
First Day OpenHK$ 68.8
First Day Change-66.42%
First Day Volume3408600.0
First Day Turnover228142000.0
Use of Proceeds
1、約506.9百萬港元(占84.0%)用于為正在進行的進口核心產品的BLA注冊,正在進行的及計劃中的本地生產核心產品的研發及BLA注冊,計劃中的新適應癥擴展臨床試驗,以及核心產品隆培促生長素 (lonapegsomatropin)的計劃商業化上市提供資金; 2、約45.7百萬港元(占7.6%)用于為正在進行的帕羅培特立帕肽(palopegteriparatide)的中國3期關鍵性試驗的開放標簽擴展研究部分及商業化上市的籌備工作提供資金; 3、約10.7百萬港元(占1.8%)用于為正在進行的那韋培肽 (navepegritide)用于治療軟骨發育不全的中國2期試驗的開放標簽擴展研究部分及相關分析提供資金; 4、約40.0百萬港元(占6.6%)用于撥付營運資金及作其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546
Sponsor cum Overall Coordinator (2)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546
Joint Global Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546
Joint Bookrunners (6)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 CLSA LIMITED CE AAB893 富途证券国际(香港)有限公司 CE AZT137 GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594 东吴证券国际经纪有限公司 CE AYA587
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 CLSA LIMITED CE AAB893 富途证券国际(香港)有限公司 CE AZT137 GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594 东吴证券国际经纪有限公司 CE AYA587 PATRONS SECURITIES LIMITED CE BPQ161 Ruibang Securities Limited CE BIJ312
Capital Market Intermediaries (8)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 CLSA LIMITED CE AAB893 富途证券国际(香港)有限公司 CE AZT137 GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594 东吴证券国际经纪有限公司 CE AYA587 PATRONS SECURITIES LIMITED CE BPQ161 Ruibang Securities Limited CE BIJ312
Stabilizing Manager (1)
Morgan Stanley Asia Limited CE AAD291

Service Providers

RoleInstitution
Legal Advisor to Company 科律香港律师事务所
君合律师事务所
Travers Thorp Alberga
Legal Advisor to Sponsors/Underwriters 达维香港律师事务所
北京市通商律师事务所
Auditor and Reporting Accountant 安永会计师事务所
Industry Advisor 弗若斯特沙利文国际有限公司
Compliance Advisor Somerley Capital Limited CE BAU754
Receiving Banks 中国工商银行(亚洲)有限公司
中国银行(香港)有限公司
招商永隆银行有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 The Reynold Lemkins Group (Asia) Limited 28,359,360 HKD — 3.60% — 6 months 2025-09-21
2 Vivo Plenilune IX Limited 70,912,160 HKD — 9.10% — 6 months 2025-09-21
3 WuXi Biologics Healthcare Venture 70,912,160 HKD — 9.10% — 6 months 2025-09-21
4 安科生物(香港)有限公司 212,729,600 HKD — 27.20% — 6 months 2025-09-21
5 园丰国际有限公司 126,364,960 HKD — 16.10% — 6 months 2025-09-21

Directors & Management

PositionChinese nameEnglish Name
Chairman付山—
Company Secretary陳詩婷—
No director data available.

Major Shareholders

Major Shareholders & HoldingsAscendis Pharma(36.58%),Vivo Plenilune IX Limited(32.14%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO saw an oversubscription of 72.64 times, indicating moderate market enthusiasm. The overall hit rate of 33.56% suggests that about one in three applicants received an allocation, a level typical for offerings with this degree of retail interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

A sharp allocation discontinuity exists between the A-tier tail (60,000 shares applied, 0.0781 expected lots) and B-tier head (70,000 shares, 0.4605 expected lots), with B-head applicants receiving nearly six times more expected lots for only a 16.7% larger application. This inefficient structure penalizes A-tail subscribers, who face relatively high broker costs per allocated share compared to those just crossing into the B tier. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data for this IPO is unavailable, so no analysis of mainland China participation, gender distribution, or regional concentration is possible. Investors should refer to official filings for any such breakdowns if they become available. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Visen Pharma-B (02561) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect